Pentixapharm Holding AG is a Germany-based clinical-stage radiopharmaceutical development company. The Company focuses on the development of radiopharmaceuticals for various therapeutic areas, as well as for the diagnosis and therapy (theranostics) of blood cancer and others. It is also engaged in holding activities and is also involved in the research and development of drugs for hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases.

Employees

Sector

Pharmaceuticals

More about the company

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.860EUR

Average target price

9.265EUR

Spread / Average Target

+398.12%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

06/08	Pentixapharm Holding AG Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06/08	Pentixapharm Holding AG and Pentixapharm AG Announce Executive Changes	CI

Market Cap	4.61Cr 5.25Cr 4.35Cr 3.97Cr 7.43Cr 503.49Cr 7.48Cr 52Cr 20Cr 257.22Cr 20Cr 19Cr 826.68Cr	P/E 2026 *	-3x	P/E 2027 *	-2.82x
Enterprise Value	3.88Cr 4.42Cr 3.66Cr 3.34Cr 6.25Cr 423.75Cr 6.3Cr 44Cr 17Cr 216.49Cr 17Cr 16Cr 695.76Cr	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	68.98%	Yield 2026 *	-	Yield 2027 *	-

06/08	Pentixapharm Holding AG Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06/08	Pentixapharm Holding AG and Pentixapharm AG Announce Executive Changes	CI
06/08	Pentixapharm Holding Ag Reaffirms Earnings Guidance for the Full Year 2026	CI
22/07	Pentixapharm Raises EUR16.8 Million via Rights Offering	MT
22/07	Eckert & Ziegler: BaFin reviews 2024 financial statements over Pentixapharm spin-off	DP
22/07	Eckert & Ziegler next in BaFin's sights, shares rebound	DP
22/07	Eckert & Ziegler Faces BaFin Review Over Pentixapharm Spin-off Accounting	MT
22/07	Eckert & Ziegler: BaFin reviews 2024 financial statements over Pentixapharm spin-off	DP
09/07	Pentixapharm Holding AG Receives FDA Fast Track Designation For Phase 3 Diagnostic Candidate [68Ga]Ga-Pentixafor In Primary Aldosteronism	CI
09/07	Pentixapharm's Underdevelopment Radiodiagnostic Gets Fast Track Designation From US FDA	MT
09/06	Pentixapharm Disputes German Regulator's Preliminary Error Findings in FY24 Financial Statements	MT
09/06	Pentixapharm Holding Ag Announces Fda Clearance of Ind for Phase 3 Panda Study of First-In-Class Cardiovascular Diagnostic Program	CI
09/06	Pentixapharm Gains US FDA Clearance for Late-stage PentixaFor Study	MT

17/08	Pentixapharm Holding AG: Eckert Wagniskapital und Frühphasenfinanzierung GmbH, Purchase of shares by exercising subscription rights	EQ
06/08	Pentixapharm Reports Second Quarter and First Half 2026 Results and Advances Phase 3 Panda Program	EQ
28/07	Pentixapharm Completes Capital Increase – New Shares Placed in Full	EQ
28/07	Pentixapharm Holding AG completes rights offering and private placement with significant oversubscription generating gross proceeds of approx. EUR 20.4 Million already today	EQ
23/07	Pentixapharm Holding AG - Ad-hoc, Rights offering successfully completed, Remaining shares can be subscribed for via private placement	AQ

Pentixapharm Holding AG Share Price OTC Markets

Stocks

PTPDF

DE000A40AEG0

Pharmaceuticals

Valuation: Pentixapharm Holding AG

Latest news: Pentixapharm Holding AG

Press Releases: Pentixapharm Holding AG

News in other languages: Pentixapharm Holding AG

Price Extremes

Other Pharmaceuticals

Financials

Company Profile

Analysts' Consensus

Annual profits - Rate of surprise

Current year	0		2.31
1 year	0		2.31
3 years	0		2.31
5 years	0		2.31
10 years	0		2.31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PENTIXAPHARM HOLDING AG	-.--%	-.--%	-	-	5.33Cr
ELI LILLY AND COMPANY	+0.13%	+2.65%	+65.61%	+114.28%	1,05300Cr
JOHNSON & JOHNSON	+0.20%	+0.46%	+52.60%	+69.24%	65TCr
ABBVIE INC.	-0.29%	+0.14%	+20.96%	+70.93%	47TCr
ROCHE HOLDING AG	-0.85%	-0.25%	+38.63%	+44.47%	35TCr
NOVARTIS AG	+0.71%	+3.26%	+22.46%	+30.30%	27TCr
ASTRAZENECA PLC	+1.23%	+1.00%	+11.97%	+13.63%	25TCr
AMGEN INC.	+2.11%	+7.51%	+52.89%	+55.37%	22TCr
GILEAD SCIENCES, INC.	+0.83%	+0.55%	+35.99%	+101.70%	19TCr
NOVO NORDISK A/S	0.00%	-9.43%	-31.91%	-60.56%	17TCr
Average	+0.36%	+0.30%	+29.91%	+48.82%	40.3TCr
Weighted average by Cap.	+0.26%	+1.00%	+41.03%	+68.05%

	2026 *	2027 *
Net sales	-	-
Net income	-2.23Cr -2.54Cr -2.11Cr -1.92Cr -3.59Cr -243.57Cr -3.62Cr -25Cr -9.76Cr -124.44Cr -9.54Cr -9.34Cr -399.92Cr	-2.35Cr -2.68Cr -2.22Cr -2.02Cr -3.79Cr -256.68Cr -3.81Cr -27Cr -10Cr -131.13Cr -10Cr -9.84Cr -421.44Cr
Net Debt	-73L -83.19L -68.95L -62.83L -1.18Cr -80Cr -1.18Cr -8.25Cr -3.2Cr -41Cr -3.12Cr -3.06Cr -130.92Cr	1.23Cr 1.4Cr 1.16Cr 1.06Cr 1.98Cr 134.35Cr 2Cr 14Cr 5.38Cr 69Cr 5.26Cr 5.15Cr 220.58Cr